Member Info for gixer

1.08 was just above the closing ask. Lets hope for a bit of buying pressure on Monday :)
http://postimg.cc/qzXTnXPW

Gone through the resistance points according to barchart.
https://www.barchart.com/stocks/quotes/PXS.LN

No, LSE
http://postimg.cc/LYg8tgSw

http://postimg.cc/w7pjNBG4

Nice to finish above 1p for a change although this site isn't showing it or any trades after 14:14.
A few 1m late reported trades as well.

This review is about vitamin D and covid but FF gets a mention.

"While not an exhaustive list, vitamins (A, B, E, and K), trace nutrients (selenium, copper, etc.), fiber, fish oils, probiotics, prebiotics, phenolic compounds (quercetin, resveratrol, etc.), phytomedicinal and natural products (elderberry, echinacea, rosemary, curcumin, bee propolis, etc.), melatonin, phosphatidylserine, collagen, and various other supplements and nutraceuticals are all being considered for the development of potential
prophylactics and therapeutics against COVID-19 [14,21,23,24,62–65]. Nutraceuticals and
supplements are also being considered for the treatment of cardiovascular-related
COVID-19 symptoms. Antiplatelet agents such as Fruitflow® have received some attention due to their potential to ameliorate the prothrombotic state associated with COVID19 [66–68]. However, most of these agents have not been tested clinically against COVID19. "

https://www.mdpi.com/2072-6643/13/3/740/pdf

Major shareholders page has been updated with new placing shares.
https://www.provexis.com/shareholder-information/major-shareholders/

Team DSM
FF gets a small mention
“We are looking for new technology and improved details in both nutrition and materials to make a difference. To give an example; in a grand tour, recovery is essential to get the best possible performance. Nutrition plays a crucial role in this. DSM has devised all kinds of ways to recover faster through nutrition and to tire less quickly. For example, by cutting proteins with the product PeptoPro, or by reducing the stress on your blood vessels via the product Fruitflow. In addition, we will continue to develop Personalized Nutrition togetherspecifically tailored to the needs of the riders. Based on all kinds of factors such as your effort, the amount of sleep or your fitness, it is determined what exactly you need in terms of nutrition. Your nutrition is therefore tailored to your life pattern. "
https://www.sportnext.nl/sponsoring/team-dsm-koppelt-topsport-aan-duurzaamheid-en-innovatie/

http://postimg.cc/DSRkVzj5

Think its just a mess up by LSE chat.
On the day of the Director / PDMR notification that page was showing all 6,666,667 against Buck when he only took 1,666,667.

Director buys need to notified to the market almost immediately and the annual report shows Buck as having 25,416,667

I assumed the £8,346 for "Fruitflow+ nitrates - in development" was part payment of the £55k due to us from By-Health for the project work on Fruitflow+ nitrates.

"Projects conducted under the agreement will be focussed on specific areas of commercial focus for By-Health,
and the first project which has been agreed will concentrate on the use of Fruitflow with nitrates in exercise,
an area of considerable commercial interest to By-Health in China. Project work will be managed and
conducted by Provexis primarily in the UK, led by Provexis’ Chief Scientific Officer Dr Niamh O’Kennedy and
supported by outsourced research partners which will be appointed and managed by Provexis.
The Fruitflow with nitrates in exercise project will require the use of healthy volunteers and it has therefore
been delayed by the COVID-19 pandemic. It is expected that the project will be re-started when it is safe to do
so, and as the project progresses it is expected to provide gross income to Provexis in excess of £55k, to
include an element of overhead recovery. The project will not affect the ownership of Provexis’ existing,
substantial intellectual property for the Fruitflow with nitrates formulation, which has potential patent protection
out to December 2033."

Not sure why the App has been delayed for so long but assume it should have been out in 2019 as its shown in these videos.
https://youtu.be/hhPBlnnCr2M?t=131
https://youtu.be/3Ih0wsIcTEE?t=99

Assuming that you mean the RNS of the 19th then I am struggling to find what you are referring to kievsky.

Does February have any relevance to PXS that I am missing?

We will see on or around the 25th but I expect there will be no change to the % holdings shown on the pxs website.

I suppose the 9% shown for SL could be wrong but that would mean he has failed to notify the market as required. IMO the 9% is correct but the number of shares shown is wrong. I don't think you need to notify the market in that case.

I make it 11,954,259.04 shares short.
He would have had to have purchased at least that many shares in the £1m placing to stay at 9% and avoid having to give a TR1.
If he purchased 12 million in the placing to keep himself above 9% then with the new placing shares this will take him bellow 9% and he will have to notify. But if he purchased more than 12,554,259.07 shares in the £1m placing then nothing changes unless the latest investor of 5,000,000 shares goes above 3%.

I hope that makes sense lol.

"As a result of the implementation of MAR, AIM Rule 21 was replaced by a requirement for AIM-listed companies to implement a share dealing policy which complies with a set of minimum requirements. The definition of a close period (redefined as a ‘closed period’) was also amended to be the 30 days prior to the release of financial results. The restrictions on dealing while in possession of unpublished price sensitive information remain.

AIM companies are required to establish appropriate closed periods (which may be more than the prescribed 30 days prior to the release of financial information) during which directors and applicable employees are restricted from dealing in the company’s shares, and create and implement procedures that directors and applicable employees are required to comply with prior to conducting any transactions in the company’s shares, in order to obtain clearance to deal. Finally, there should also be a procedure in place requiring notifications of dealings in the company’s shares to be disclosed to the company in order that the company can notify transactions which are required to be made public."

The news of the distributor is in the public domain so I doubt knowing who the distributor is would be classed as price sensitive. The above would suggest however that as the company was in a closed period then Buck could not have participated in the fund raise at the time.
https://www.reedsmith.com/en/perspectives/2016/11/changes-to-the-aim-rules

As it is never made clear, everyone assumes Buck does very little with regards to company business which I am sure is not the case. But, as a company, we need someone in the position and you would struggle to get anyone with his knowledge of the product for £36k a year. Far less than it used to be.

I am sure there is a simple reason why Buck didn't buy in the original placing and as he spent 1/3 of his salary on them he must have been keen.

Does he not have options that would have been at a better price?

DP64, No it means the opposite. We (PXS) has the IP so its protected.

Think you should check your figures pumpky. They are way out.

Only guessing but looks like an investor maybe missed out the last time or didn't get his full allocation for whatever reason and Buck has topped it up to a round number. BWTFDIK :)

3 other updates this year.
FRUIT EXTRACTS
2021-01-25

A COMPOSITION COMPRISING A TOMATO EXTRACT FOR PREVENTING SYSTEMIC INFLAMMATION
2021-02-17

WATER SOLUBLE TOMATO EXTRACT PROTECTS AGAINST ADVERSE EFFECTS OF AIR POLLUTION
2021-02-02

https://worldwide.espacenet.com/searchResults?submitted=true&locale=en_EP&DB=EPODOC&ST=advanced&TI=&AB=&PN=&AP=&PR=&PD=&PA=provexis&IN=&CPC=&IC=

Japan.
Use of tomato extract as an antihypertensive drug and method for producing water-soluble sugar-free tomato extract

We entered into an agreement to purchased the IP from Inven2 (Oslo Uni) on 13 August 2020 and by 17 Sept 2020 had applied for the patent in Japan.

https://patentscope.wipo.int/search/en/detail.jsf?docId=JP317327143&_cid=P22-KLBVQO-57692-1